These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15970476)

  • 1. Uremic cardiomyopathy: role of circulating digitalis like substances.
    Mohmand B; Malhotra DK; Shapiro JI
    Front Biosci; 2005 Sep; 10():2036-44. PubMed ID: 15970476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling.
    Kennedy DJ; Malhotra D; Shapiro JI
    Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):3-14. PubMed ID: 17535729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy.
    Hayashi T; Ijiri Y; Toko H; Shimomura H; Okabe M; Terasaki F; Kitaura Y; Kawamura K
    Eur Heart J; 2000 Feb; 21(4):296-305. PubMed ID: 10653677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digitalis in chronic renal insufficiency.
    Rambausek M; Ritz E
    Blood Purif; 1985; 3(1-3):4-14. PubMed ID: 3006726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat.
    Priyadarshi S; Valentine B; Han C; Fedorova OV; Bagrov AY; Liu J; Periyasamy SM; Kennedy D; Malhotra D; Xie Z; Shapiro JI
    Kidney Int; 2003 May; 63(5):1785-90. PubMed ID: 12675854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy.
    Kennedy DJ; Vetteth S; Periyasamy SM; Kanj M; Fedorova L; Khouri S; Kahaleh MB; Xie Z; Malhotra D; Kolodkin NI; Lakatta EG; Fedorova OV; Bagrov AY; Shapiro JI
    Hypertension; 2006 Mar; 47(3):488-95. PubMed ID: 16446397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na/K-ATPase, endogenous digitalis like compounds and cancer development -- a hypothesis.
    Weidemann H
    Front Biosci; 2005 Sep; 10():2165-76. PubMed ID: 15970485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
    Wang X; Liu J; Drummond CA; Shapiro JI
    Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemodialysis cardiomyopathy or uremic cardiomyopathy?].
    Dongradi G; Fendler JP
    Nouv Presse Med; 1977 Jun; 6(23):2035-6. PubMed ID: 887400
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of renal transplantation on uremic cardiomyopathy.
    Parfrey PS; Harnett JD; Foley RN; Kent GM; Murray DC; Barre PE; Guttmann RD
    Transplantation; 1995 Nov; 60(9):908-14. PubMed ID: 7491692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Uremic cardiomyopathy].
    Tsuzuki K
    Ryoikibetsu Shokogun Shirizu; 1997; (16 Pt 1):56-9. PubMed ID: 9277683
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cardiac manifestations of terminal kidney insufficiency. Current characterization of uremic cardiomyopathy].
    Josephs W; Odenthal HJ
    Dtsch Med Wochenschr; 1995 Feb; 120(5):141-4. PubMed ID: 7843032
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advances in nephrology. Uremic cardiomyopathy].
    Sicinski A
    Pol Arch Med Wewn; 1976 Jan; 55(1):89-97. PubMed ID: 1250737
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function.
    Periyasamy SM; Chen J; Cooney D; Carter P; Omran E; Tian J; Priyadarshi S; Bagrov A; Fedorova O; Malhotra D; Xie Z; Shapiro JI
    Kidney Int; 2001 Dec; 60(6):2367-76. PubMed ID: 11737612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial dysfunction in uremic cardiomyopathy.
    Taylor D; Bhandari S; Seymour AM
    Am J Physiol Renal Physiol; 2015 Mar; 308(6):F579-87. PubMed ID: 25587120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction.
    Balzan S; Neglia D; Ghione S; D'Urso G; Baldacchino MC; Montali U; L'Abbate A
    Eur J Heart Fail; 2001 Mar; 3(2):165-71. PubMed ID: 11246053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central Role for Adipocyte Na,K-ATPase Oxidant Amplification Loop in the Pathogenesis of Experimental Uremic Cardiomyopathy.
    Sodhi K; Wang X; Chaudhry MA; Lakhani HV; Zehra M; Pratt R; Nawab A; Cottrill CL; Snoad B; Bai F; Denvir J; Liu J; Sanabria JR; Xie Z; Abraham NG; Shapiro JI
    J Am Soc Nephrol; 2020 Aug; 31(8):1746-1760. PubMed ID: 32587074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic abnormalities and uremic cardiomyopathy.
    Stewart GA; Gansevoort RT; Mark PB; Rooney E; McDonagh TA; Dargie HJ; Stuart R; Rodger C; Jardine AG
    Kidney Int; 2005 Jan; 67(1):217-26. PubMed ID: 15610245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular electrophysiologic effects of vertebrate digitalis-like substances.
    Kieval RS; Butler VP; Derguini F; Bruening RC; Rosen MR
    J Am Coll Cardiol; 1988 Mar; 11(3):637-43. PubMed ID: 2830326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts in the pathogenesis of uraemic cardiomyopathy.
    Wang X; Shapiro JI
    Nat Rev Nephrol; 2019 Mar; 15(3):159-175. PubMed ID: 30664681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.